Assessment of Proteomics Analysis on Plasma from Anlotinib-Treated Advanced Non-Small Cell Lung Cancer Patients
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 09 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer